. Also, patients >20 years old, and those >40 years old had significantly more anti-HAV IgG seropositivity compared to those who are younger in age (OR: 11.4, p<0.0001 and OR: 3.8, p<0.01 respectively 
(14)
Introduction
It is well known that acute hepatitis A virus (HAV) infection in patients with chronic liver disease (CLD) carries a higher mortality [1] . This Based on these data, the Advisory Committee on Immunization Practices has recommended that all patients with CLD should be immunized against HAV infection [3] .To answer the question of whether adult patients with CLD need a HAV vaccine to prevent HAV superinfection, it is important to determine the prevalence of protective IgG antibodies against HAV(anti-HAV IgG) in this population. In developed countries, the prevalence of such antibodies in adults is low and hence, the recommendation of administering HAV vaccine in adult CLD patients routinely is not only justified, but may also be cost-effective [2, 3] . Egypt has a high population of patients with CLD, especially those related to HCV infection [4] [5] [6] . Little is known about the prevalence of HAV seropositivity (immunity) or susceptibility in patients with CLD. Therefore, the present analysis was done to determine the seroprevalence of HAV infection in adult patients with CLD to assess the feasibility of routine HAV vaccination for such patients.
Patients and Methods

Patients
A total of 638 consecutive patients with chronic liver disease, 
Hepatitis A virus serology
Sera were tested for total anti-HAV which detect both IgG and IgM; and for anti-HAV IgM by using AxSYM system (Abbott Diagnostics, USA), which apply a micro particle enzymatic assay.
Briefly; the anti-HAV in samples bound to the micro particles, the resulting complex was then transferred to the glass fiber 
Results
Out of 638 patients with chronic liver diseases, only 190 (29.8 %) were tested for anti-HAV (study population). (2). reported by several studies [9] [10] [11] .
Discussion
Improvement
According to the current data, only 30 % of patients with CLD get tested for HAV serology in our locality. This indicates that doctors need to be more aware of the need to test high risk groups. In addition, HAV serology need to be tested in patient with CLD with recent decompensation of deterioration. We believe that, the more the number of patients who get tested, the higher the number of susceptible cases to HAV infection will be discovered, the higher the number of those who will need to be vaccinated. A similar case was reported
in Saudi Arabia, where many studies [12] [13] [14] [15] 
